Jared Weiss

6.0k total citations · 2 hit papers
104 papers, 2.2k citations indexed

About

Jared Weiss is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, Jared Weiss has authored 104 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 57 papers in Oncology and 38 papers in Otorhinolaryngology. Recurrent topics in Jared Weiss's work include Lung Cancer Treatments and Mutations (49 papers), Head and Neck Cancer Studies (37 papers) and Lung Cancer Research Studies (24 papers). Jared Weiss is often cited by papers focused on Lung Cancer Treatments and Mutations (49 papers), Head and Neck Cancer Studies (37 papers) and Lung Cancer Research Studies (24 papers). Jared Weiss collaborates with scholars based in United States, Japan and Germany. Jared Weiss's co-authors include Bhishamjit S. Chera, Juneko E. Grilley‐Olson, D. Neil Hayes, Thomas E. Stinchcombe, Robert J. Amdur, Mark C. Weissler, Shlomo A. Koyfman, Adam M. Zanation, Alexander Drilon and Trevor Hackman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Jared Weiss

100 papers receiving 2.1k citations

Hit Papers

Tumour-agnostic efficacy and safety of selpercati... 2019 2026 2021 2023 2022 2019 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
    2022 244 citations Vivek Subbiah, Jürgen Wolf et al. The Lancet Oncology profile →
  2. Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline
    2019 223 citations Jared Weiss et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jared Weiss United States 24 1.1k 1.1k 730 630 430 104 2.2k
Cordula Petersen Germany 32 981 0.9× 1.0k 1.0× 395 0.5× 624 1.0× 425 1.0× 116 2.7k
Michela Buglione Italy 23 988 0.9× 654 0.6× 660 0.9× 431 0.7× 279 0.6× 121 2.1k
Adriano Paccagnella Italy 21 1.2k 1.1× 1.4k 1.3× 826 1.1× 757 1.2× 462 1.1× 62 2.5k
Andrzej Kawecki Poland 11 1.4k 1.3× 1.8k 1.7× 1.6k 2.2× 923 1.5× 717 1.7× 46 3.1k
Meredith A. Goldwasser United States 17 969 0.9× 1.4k 1.3× 670 0.9× 558 0.9× 875 2.0× 29 2.7k
Katja Lindel Germany 22 466 0.4× 708 0.7× 471 0.6× 610 1.0× 322 0.7× 60 1.9k
Javier Martínez‐Trufero Spain 20 1.1k 1.1× 976 0.9× 519 0.7× 533 0.8× 199 0.5× 124 2.0k
Yusuke Onozawa Japan 23 902 0.8× 718 0.7× 395 0.5× 656 1.0× 239 0.6× 129 1.7k
W. Van den Bogaert Belgium 23 936 0.9× 722 0.7× 848 1.2× 686 1.1× 194 0.5× 69 2.4k
Wen-Fei Li China 23 592 0.6× 920 0.9× 1.0k 1.4× 662 1.1× 167 0.4× 63 1.9k

Countries citing papers authored by Jared Weiss

Since Specialization
Citations

This map shows the geographic impact of Jared Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jared Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jared Weiss more than expected).

Fields of papers citing papers by Jared Weiss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jared Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jared Weiss. The network helps show where Jared Weiss may publish in the future.

Co-authorship network of co-authors of Jared Weiss

This figure shows the co-authorship network connecting the top 25 collaborators of Jared Weiss. A scholar is included among the top collaborators of Jared Weiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jared Weiss. Jared Weiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stover, Angela M., Allison M. Deal, Ashley A. Weiner, et al.. (2025). Feasibility, Acceptability, and Utility of Remote Patient-Reported Outcomes Monitoring in Patients With Lung Cancer: A Moovcare© Study. Clinical Lung Cancer. 26(8). e660–e669.e1.
2.
Patel, Shetal, Young E. Whang, Kevin Chen, et al.. (2024). Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report. JTO Clinical and Research Reports. 5(10). 100712–100712. 5 indexed citations
3.
Cerise, Jane, et al.. (2024). The age-specific microbiome of children with milk, egg, and peanut allergy. Annals of Allergy Asthma & Immunology. 133(2). 203–210.e6. 2 indexed citations
4.
Marmarelis, Melina E., Caroline E. McCoach, Geoffrey Liu, et al.. (2023). Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology. 41(16_suppl). 9116–9116.
5.
Subbiah, Vivek, Jürgen Wolf, Bhavana Konda, et al.. (2022). Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. The Lancet Oncology. 23(10). 1261–1273. 244 indexed citations breakdown →
6.
Weiss, Jared, Siddharth Sheth, Allison M. Deal, et al.. (2020). Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication. Clinical Cancer Research. 26(16). 4260–4267. 29 indexed citations
7.
Chera, Bhisham, Robert J. Amdur, Colette J. Shen, et al.. (2018). Initial Results from a Phase 2 Prospective Trial of De-intensified Chemoradiation therapy for Low-Risk HPV-associated Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1309–1310. 2 indexed citations
8.
9.
Drilon, Alexander, Jeffrey W. Clark, Jared Weiss, et al.. (2018). OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S348–S348. 24 indexed citations
10.
Langer, Corey J., Edward S. Kim, Eric Anderson, et al.. (2018). nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC. Frontiers in Oncology. 8. 262–262. 7 indexed citations
11.
Pearlstein, Kevin A., Kyle Wang, Robert J. Amdur, et al.. (2018). Quality of Life for Patients With Favorable-Risk HPV-Associated Oropharyngeal Cancer After De-intensified Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics. 103(3). 646–653. 24 indexed citations
12.
Yu, Helena A., Alexander I. Spira, Leora Horn, et al.. (2017). A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations. Clinical Cancer Research. 23(24). 7467–7473. 23 indexed citations
13.
Drilon, A., Sai‐Hong Ignatius Ou, Jeffrey W. Clark, et al.. (2017). MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S438–S439. 12 indexed citations
14.
Chera, Bhishamjit S., Robert J. Amdur, Joel E. Tepper, et al.. (2015). A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 93(3). S2–S2. 4 indexed citations
15.
Lee, Carrie B., et al.. (2015). MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor. Journal of Thoracic Oncology. 10(12). e113–e114. 38 indexed citations
16.
Weiss, Jared, Liza C. Villaruz, Jonathon J. O’Brien, et al.. (2015). Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non–Small Cell Lung Cancer. Clinical Lung Cancer. 17(2). 128–132. 7 indexed citations
17.
Malhotra, Binu, Tracey L. Evans, Jared Weiss, et al.. (2010). Carboplatin/Pemetrexed/Bevacizumab in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Single-Institution Experience. Clinical Lung Cancer. 11(3). 192–197. 10 indexed citations
18.
Weiss, Jared, Beth Eaby, James Stevenson, et al.. (2010). Adjuvant Cisplatin and Docetaxel for Non-small Cell Lung Cancer: The Hospital of the University of Pennsylvania Experience. Journal of Thoracic Oncology. 5(5). 667–672. 3 indexed citations
19.
Weiss, Jared & Corey J. Langer. (2009). NSCLC in the Elderly—The Legacy of Therapeutic Neglect. Current Treatment Options in Oncology. 10(3-4). 180–194. 8 indexed citations
20.
Schöber, C., Hans‐Joachim Schmoll, H. Poliwoda, et al.. (1992). Antitumour effect and symptomatic control with interferon α2b in patients with endocrine active tumours. European Journal of Cancer. 28(10). 1664–1666. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cordula Petersen Breakdown of academic impact, for papers by Michela Buglione Breakdown of academic impact, for papers by Adriano Paccagnella Breakdown of academic impact, for papers by Andrzej Kawecki Breakdown of academic impact, for papers by Meredith A. Goldwasser Breakdown of academic impact, for papers by Katja Lindel Breakdown of academic impact, for papers by Javier Martínez‐Trufero Breakdown of academic impact, for papers by Yusuke Onozawa Breakdown of academic impact, for papers by W. Van den Bogaert Breakdown of academic impact, for papers by Wen-Fei Li
Rankless by CCL
2026